PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression
Oncology Research · 2026 · 34 (7) · 1-10
DOI: 10.32604/or.2026.079316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Yangyang Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Galectins, Hepatitis A Virus Cellular Receptor 2, Prostatic Neoplasms, Positive Regulatory Domain I-Binding Factor 1. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Institute of Urology, Anhui Medical University, Hefei, China.
- Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China.
- Department of Anesthesiology, Shanghai Xuhui Central Hospital, Shanghai, China.
- West China Medical Center, Sichuan University, Chengdu, China.
Zitieren
APA
Zhang, Y., Mamtili, I., Chen, Y., Ji, G., & Liang, C. (2026). PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression. Oncology Research, 34(7), 1-10. https://doi.org/10.32604/or.2026.079316
Vancouver
Zhang Y, Mamtili I, Chen Y, Ji G, Liang C. PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression. Oncology Research. 2026;34(7):1-10. doi:10.32604/or.2026.079316
BibTeX
@article{Zhang2026,
author = {Zhang, Yangyang and Mamtili, Ilyar and Chen, Yonghao and Ji, Guangjie and Liang, Chaozhao},
title = {PRDM1 Drives a TIM3+ Macrophage Immunosuppressive Niche via LGALS9 Signaling in Prostate Cancer Progression},
journal = {Oncology Research},
year = {2026},
volume = {34},
number = {7},
pages = {1--10},
doi = {10.32604/or.2026.079316}
}
EUVIMED